AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22030215
Drug: Dexmedetomidine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine infusion at a constant rate for the first 12 hours, then titrated between 0.1 and 2.5 μg/kg/h for up to 14 days.
Trial: 22030975
Drug: Swallowing 14.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swallowing 14.5 ml of water
Trial: 22030975
Drug: Swallowing 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swallowing 20 ml of water
Trial: 22030975
Drug: Swallowing 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swallowing 100 ml of water
Trial: 22033282
Drug: Mocetinostat 110
RxNorm normalized name: Mocetinostat
DrugBank: Mocetinostat (DB11830)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mocetinostat 110 mg, administered orally three times per week
Trial: 22033282
Drug: Mocetinostat 85
RxNorm normalized name: Mocetinostat
DrugBank: Mocetinostat (DB11830)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mocetinostat 85 mg, administered orally three times per week
Trial: 22033282
Drug: Mocetinostat 110
RxNorm normalized name: Mocetinostat
DrugBank: Mocetinostat (DB11830)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mocetinostat 110 mg
Trial: 22033282
Drug: Mocetinostat 85
RxNorm normalized name: Mocetinostat
DrugBank: Mocetinostat (DB11830)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mocetinostat 85 mg
Trial: 22033322
Drug: Temsirolimus 75
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Temsirolimus 75 mg/m(2) administered once weekly until disease progression or intolerance
Trial: 22033493
Drug: Sequential azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sequential azacitidine and lenalidomide
Trial: 22033636
Drug: Sorafenib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 400 mg/bid continuously and 5-fluorouracil 200 mg/sqm/daily day 1-14 every 3 weeks
Trial: 22034233
Drug: Concurrent septoplasty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent septoplasty during endoscopic sinus surgery (ESS) (n = 108)
Trial: 22034233
Drug: Concurrent septoplasty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent septoplasty during endoscopic sinus surgery (ESS)
Trial: 22035417
Drug: Yttrium-90 ibritumomab
RxNorm normalized name: yttrium
DrugBank: Yttrium Y-90 (DB13076)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yttrium-90 ibritumomab tiuxetan consolidation treatment after R-CHOP chemotherapy
Trial: 22035806
Drug: Paclitaxel (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (175 mg/m(2)) and carboplatin (AUC=6.0-7.5) every 21 days for 3 doses, followed by radiation therapy, followed by an additional 3 cycles of paclitaxel and carboplatin (AUC=5-6)
Trial: 22036135
Drug: Uric acid
RxNorm normalized name: Uric acid
DrugBank: Uric acid (DB08844)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uric acid ≥ 5.0 mg/dL
Trial: 22036634
Drug: bosutinib therapy
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: bosutinib therapy
Trial: 22037543
Drug: Sublingual temperature
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual temperature measurement
Trial: 22038064
Drug: Weight loss
RxNorm normalized name: HERBAL WEIGHT LOSS AID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight loss therapy for 1 year
Trial: 22040109
Drug: BM-MNC as
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BM-MNC as a cell therapy product
Trial: 22044606
Drug: Pemetrexed 500
RxNorm normalized name: pemetrexed 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 500 mg/m(2) and carboplatin AUC 6
Trial: 22045986
Drug: Intratumoral injection
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intratumoral injection of a TLR9 agonist combined with radiation
Trial: 22047558
Drug: AP1903 (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AP1903 (a small-molecule dimerizing drug)
Trial: 28403055
Drug: PHiD-CV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHiD-CV vaccine
Trial: 22050371
Drug: Adjunctive levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adjunctive levetiracetam (LEV) at individualized doses (1,000-4,000 mg/day; 20-80 mg/kg/day for children/adolescents weighing <50 kg)
Trial: 22050371
Drug: Adjunctive levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adjunctive levetiracetam (LEV)
Trial: 22050987
Drug: Urine albumin
RxNorm normalized name: urine albumin test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urine albumin to creatinine ratio categories (≤ 10 mg/g, 11-29 mg/g, 30-299 mg/g, ≥ 300 mg/g)
Trial: 22052198
Drug: Protocol-driven treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol-driven treatment (fixed metformin and glargine, insulin adjusted according to sliding scale)
Trial: 22052619
Drug: Temozolomide 200
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide 200 mg/m(2) orally for 7 days every 4 weeks (methylated MGMT - mMGMT)
Trial: 22052619
Drug: Temozolomide 100
RxNorm normalized name: temozolomide 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temozolomide 100 mg/m(2) orally for 14 days followed by 200 mg/m(2) orally for 7 days every 6 weeks (unmethylated MGMT - unMGMT)
Trial: 22056381
Drug: IL-12 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-12 treatment
Trial: 22056644
Drug: High-dose immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose immunosuppressive therapy (HDIT) followed by autologous hematopoietic cell transplantation (AHCT)
Trial: 22058200
Drug: Lenalidomide 25
RxNorm normalized name: lenalidomide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 25 mg/day (days 1-21 of each 28-day cycle) and dexamethasone (40 mg/day on days 1, 8, 15, and 22) for up to 12 months
Trial: 22058224
Drug: Platelet count
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet count in the first quartile on treatment day 33
Trial: 22058224
Drug: Platelet counts
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet counts after induction treatment
Trial: 22067102
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily insulin regimen with long acting insulin analogue (LAIA) at dinner
Trial: 22067102
Drug: Three times
RxNorm normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three times daily insulin regimen (standard TID regimen)
Trial: 22067102
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily insulin regimen with LAIA at dinner
Trial: 22068254
Drug: Metreleptin treatment
RxNorm normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metreleptin treatment (subcutaneous injections once or twice daily)
Trial: 22068813
Drug: Balanced diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced diet (55 En% carbohydrates, 30 En% fat, 15 En% proteins) and exercise therapy once a week
Trial: 22068813
Drug: Balanced diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced diet and exercise therapy
Trial: 22069451
Drug: Isoniazid preventive
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid preventive therapy (IPT) for children ≤5 years old, duration of 6 months.
Trial: 22071596
Drug: Afatinib 50
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Afatinib 50 mg/day
Trial: 22071596
Drug: Afatinib 20-50
RxNorm normalized name: afatinib 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib 20-50 mg/day
Trial: 22074178
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g PinnoThin TAG
Trial: 22074178
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g PinnoThin TAG
Trial: 22074813
Drug: Stimulant +
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant + Parent Training
Trial: 22074813
Drug: Stimulant +
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant + Antipsychotic (Risperidone) + Parent Training
Trial: 22077194
Drug: Preoperative intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative intravenous antibiotics
Trial: 22077194
Drug: Postoperative systemic
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative systemic antibiotic therapy (68.7% of patients)
Trial: 22077194
Drug: Povidone-iodine for
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone-iodine for topical antisepsis (used by sites with infection rates >5%)
Trial: 22078932
Drug: Linifanib 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linifanib 0.25 mg/kg/day
Trial: 22079051
Drug: Single Shot
RxNorm normalized name: ACL7 SINGLE SHOT EPIDURAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Shot 3D-CRT Partial Breast Irradiation (SSPBI) with a dose of 21 Gy
Trial: 22079876
Drug: Intramuscular infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular infusion of a combination cell product
Trial: 22079961
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of 1.25 mg bevacizumab (BCZ)
Trial: 22086881
Drug: High-dose calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose calcium channel blockade as monotherapy or combination therapy
Trial: 22087267
Drug: Inactivated, monovalent,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated, monovalent, non-adjuvanted pandemic (H1N1) 2009 vaccine
Trial: 22087555
Drug: Treatment-as-usual at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual at inpatient family clinics
Trial: 22088989
Drug: Crizotinib (dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crizotinib (dual MET/ALK inhibitor)
Trial: 22090362
Drug: PD 0332991
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PD 0332991 at 125 mg once daily
Trial: 22093200
Drug: Adenosine diphosphate
RxNorm normalized name: Adenosine diphosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine diphosphate (ADP) receptor inhibitors
Trial: 22093206
Drug: Myeloperoxidase (MPO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myeloperoxidase (MPO) measured at arrival with a cutpoint of 210 ng/mL
Trial: 22094934
Drug: Preoperative paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Preoperative paclitaxel (80 mg/m²) and gemcitabine (1,200 mg/m²) with weekly trastuzumab for 6 cycles, followed by 1 year of trastuzumab and 5 years of hormone therapy if indicated.
Trial: 22094934
Drug: Preoperative paclitaxel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative paclitaxel, gemcitabine, and trastuzumab (PGH) combination therapy.
Trial: 22100149
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg daily and bevacizumab 15 mg/kg every 3 weeks (Module A)
Trial: 22100149
Drug: Carboplatin (AUC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (AUC = 6), paclitaxel 200 mg/m2, and bevacizumab 15 mg/kg for 4 cycles (Module B)
Trial: 22100149
Drug: Maintenance erlotinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance erlotinib 150 mg daily and bevacizumab 15 mg/kg every 3 weeks (Module C)
Trial: 22102646
Drug: 0.5 g/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g/kg/day intravenous undiluted alanyl-glutamine
Trial: 22102709
Drug: Intensification therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensification therapy
Trial: 22102709
Drug: Molecular remission
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Molecular remission after induction chemotherapy
Trial: 22105591
Drug: Posaconazole 600-800
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole 600-800 mg/d
Trial: 22105720
Drug: Oral 3-AP
RxNorm normalized name: AP
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral 3-AP at 150 mg per dose
Trial: 22105720
Drug: Intravenous 3-AP
RxNorm normalized name: AP
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous 3-AP at 100 mg
Trial: 22105799
Drug: Anti-retinal antibody
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-retinal antibody analysis
Trial: 22105894
Drug: Imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib mesylate at a dose of 400 mg/day for 1 year after surgery
Trial: 22106377
Drug: Supervised, on-site
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised, on-site standard (10 h) dose of Road Tour training
Trial: 22106377
Drug: Supervised, on-site
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised, on-site standard dose of Road Tour training with 4 h of subsequent booster training
Trial: 22106377
Drug: Self-administered, at-home
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered, at-home standard dose of Road Tour training
Trial: 22106377
Drug: Supervised, on-site
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised, on-site standard dose of attention control (crossword puzzles) training
Trial: 22106730
Drug: Calcitriol ointment
RxNorm normalized name: Calcitriol Ointment
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcitriol ointment 3 microg/g applied twice daily on weekdays and clobetasol propionate spray 0.05% applied twice daily on weekends for up to 4 weeks
Trial: 22109661
Drug: Real-time magnetic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Real-time magnetic resonance-guided laser-induced thermal therapy (MRgLITT)
Trial: 22110166
Drug: Low-dose bacterial
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose bacterial endotoxin
Trial: 22114900
Drug: Ropivacaine 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 7.5 mg/ml, 20 ml infiltration
Trial: 22115634
Drug: First dose
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First dose of Tdap vaccine (naïve group)
Trial: 22115634
Drug: Repeat dose
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat dose of Tdap vaccine (repeat-dose group)
Trial: 22115634
Drug: Repeat-dose group
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat-dose group
Trial: 25418910
Drug: LVR-coil treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LVR-coil treatment
Trial: 22117586
Drug: Influenza A
RxNorm normalized name: influenza A virus
DrugBank: Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) (DB14444)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza A H1N1/09 AS03 adjuvanted vaccine (3.75 mg of haemagglutinin, two doses at 3-4 week interval)
Trial: 22123298
Drug: Electrochemiluminescence (ECL)
RxNorm normalized name: 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ECL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrochemiluminescence (ECL) assay for insulin autoantibodies (IAA)
Trial: 22123298
Drug: Electrochemiluminescence (ECL)
RxNorm normalized name: 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ECL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrochemiluminescence (ECL) assay for anti-insulin antibodies (IA)
Trial: 22127697
Drug: Tumor necrosis
RxNorm normalized name: Tumor necrosis factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor necrosis factor α (TNFα) inhibitors
Trial: 22127927
Drug: cediranib, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cediranib, a pan-VEGF receptor tyrosine kinase inhibitor
Trial: 22129044
Drug: Everolimus and
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus and low-dose oral cyclophosphamide
Trial: 22129253
Drug: Low-dose interleukin-2
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-dose interleukin-2 (1.5 million IU per day for 5 days, followed by three 5-day courses of 3 million IU per day at weeks 3, 6, and 9)
Trial: 22129252
Drug: Low-dose subcutaneous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose subcutaneous interleukin-2 (0.3×10(6), 1×10(6), or 3×10(6) IU per square meter of body-surface area) for 8 weeks
Trial: 22133770
Drug: Subcutaneous alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous alemtuzumab 10 mg/day for 3 days and intravenous rituximab 100 mg on Days +4, +11, +18, and +25
Trial: 22137491
Drug: Cancer therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cancer therapies (specifics not provided)
Trial: 22137491
Drug: Alkylating agent
RxNorm normalized name: Alkylating agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alkylating agent dose score
Trial: 22137491
Drug: High-dose cancer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cancer therapy
Trial: 22139909
Drug: ARRY-520 single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARRY-520 single-dose schedule (dose levels: 2.5, 3.75, 4.5, and 5.6 mg/m(2))
Trial: 22139909
Drug: ARRY-520 divided-dose
RxNorm normalized name: ARRY-502
DrugBank: ARRY-502 (DB16053)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARRY-520 divided-dose schedule (dose levels: 0.8, 1.2, 1.5, and 1.8 mg/m(2)/day)
Trial: 22140209
Drug: Paper prescriptions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paper prescriptions
Trial: 22141572
Drug: +183 G-allele
FDA approved: no
EMA approved: no
PMDA approved: no
Description: +183 G-allele
Trial: 22141572
Drug: +183 G-alleles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: +183 G-alleles
Trial: 22145984
Drug: Olaparib 100
RxNorm normalized name: olaparib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib 100 mg b.i.d.
Trial: 22145984
Drug: Olaparib 200
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 200 mg b.i.d.
Trial: 22145984
Drug: Olaparib 400
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 400 mg b.i.d.
Trial: 22147631
Drug: Selective Serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective Serotonin Reuptake Inhibitor (SSRI) treatment for depression for 2 weeks
Trial: 22149959
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of scAAV2/8-LP1-hFIXco
Trial: 22149959
Drug: Intermediate dose
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate dose of scAAV2/8-LP1-hFIXco
Trial: 22149959
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of scAAV2/8-LP1-hFIXco
Trial: 22149959
Drug: scAAV2/8-LP1-hFIXco (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: scAAV2/8-LP1-hFIXco (all doses)
Trial: 22152120
Drug: Neo-adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neo-adjuvant chemotherapy (EIA: etoposide 125 mg/m² iv days 1 and 4, ifosfamide 1500 mg/m² iv days 1 - 4, doxorubicin 50 mg/m² day 1, pegfilgrastim 6 mg sc day 5) followed by definitive surgery with intra-operative radiotherapy, adjuvant radiotherapy and 4 adjuvant cycles of EIA.
Trial: 22152427
Drug: Sports Drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sports Drink (SPD: CHOs 68.6 g.L-1, BCAAs 4 g.L-1, caffeine 75 mg.L-1)
Trial: 22153792
Drug: Infliximab 5
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab 5 mg/kg intravenous infusions at weeks 0, 2, 6, 14, and 22
Trial: 22154896
Drug: SODAS dexmethylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SODAS dexmethylphenidate 20 mg
Trial: 22154896
Drug: SODAS dexmethylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SODAS dexmethylphenidate 30 mg